Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12
- PMID: 26289956
- DOI: 10.1016/S1473-3099(15)00059-6
Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12
Abstract
Background: Safety data from countries with experience in the use of inactivated poliovirus vaccine (IPV) are important for the global polio eradication strategy to introduce IPV into the immunisation schedules of all countries. In the USA, IPV has been included in the routine immunisation schedule since 1997. We aimed to analyse adverse events after IPV administration reported to the US Vaccine Adverse Event Reporting System (VAERS).
Methods: We analysed all VAERS data associated with IPV submitted between Jan 1, 2000, and Dec 31, 2012, either as individual or as combination vaccines, for all age and sex groups. We analysed the number and event type (non-serious, non-fatal serious, and death reports) of individual reports, and explored the most commonly coded event terms to describe the adverse event. We classified death reports according to previously published body-system categories (respiratory, cardiovascular, neurological, gastrointestinal, other infectious, and other non-infectious) and reviewed death reports to identify the cause of death. We classified sudden infant death syndrome as a separate cause of death considering previous concerns about sudden infant syndrome after vaccines. We used empirical Bayesian data mining methods to identify disproportionate reporting of adverse events for IPV compared with other vaccines. Additional VAERS data from 1991 to 2000 were analysed to compare the safety profiles of IPV and oral poliovirus vaccine (OPV).
Findings: Of the 41,792 adverse event reports submitted, 39,568 (95%) were for children younger than 7 years. 38,381 of the reports for children in this age group (97%) were for simultaneous vaccination with IPV and other vaccines (most commonly pneumococcal and acellular pertussis vaccines), whereas standalone IPV vaccines accounted for 0·5% of all reports. 34,880 reports were for non-serious events (88%), 3905 reports were for non-fatal serious events (10%), and 783 reports were death reports (2%). Injection-site erythema was the most commonly coded term for non-serious events (29%), and pyrexia for non-fatal serious events (38%). Most deaths (96%) were in children aged 12 months or younger; most (52%) had sudden infant death syndrome as the reported cause of death. The safely profiles of combined IPV and whole-cell pertussis vaccines, OPV and whole-cell pertussis vaccines, and OPV and acellular pertussis vaccines were similar. We noted no indication of disproportionate reporting of adverse events after immunisation with IPV-containing vaccines compared with other vaccines between 1990 and 2013.
Interpretation: Fairly few adverse events were reported for the more than 250 million IPV doses distributed between 2000 and 2012. Sudden infant death syndrome reports after IPV were consistent with reporting patterns for other vaccines. No new or unexpected vaccine safety problems were identified for fatal, non-fatal serious, and non-serious reports in this assessment of adverse events after IPV.
Funding: None.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Comment in
-
Good news for billions of children who will receive IPV.Lancet Infect Dis. 2015 Oct;15(10):1120-1122. doi: 10.1016/S1473-3099(15)00099-7. Epub 2015 Aug 16. Lancet Infect Dis. 2015. PMID: 26289957 No abstract available.
Similar articles
-
Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.Pediatrics. 2001 May;107(5):E83. doi: 10.1542/peds.107.5.e83. Pediatrics. 2001. PMID: 11331733
-
Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.Cochrane Database Syst Rev. 2019 Dec 5;12(12):CD011260. doi: 10.1002/14651858.CD011260.pub2. Cochrane Database Syst Rev. 2019. PMID: 31801180 Free PMC article.
-
Vaccines to Children: Protective Effect and Adverse Events: A Systematic Review [Internet].Stockholm: Swedish Council on Health Technology Assessment (SBU); 2009 Feb. SBU Yellow Report No. 191. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2009 Feb. SBU Yellow Report No. 191. PMID: 28876765 Free Books & Documents. Review.
-
Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.Lancet Infect Dis. 2015 Nov;15(11):1273-82. doi: 10.1016/S1473-3099(15)00219-4. Epub 2015 Aug 26. Lancet Infect Dis. 2015. PMID: 26318714 Clinical Trial.
-
Administering Multiple Injectable Vaccines During a Single Visit-Summary of Findings From the Accelerated Introduction of Inactivated Polio Vaccine Globally.J Infect Dis. 2017 Jul 1;216(suppl_1):S152-S160. doi: 10.1093/infdis/jix054. J Infect Dis. 2017. PMID: 28838188 Free PMC article. Review.
Cited by
-
Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.MMWR Morb Mortal Wkly Rep. 2023 Dec 8;72(49):1327-1330. doi: 10.15585/mmwr.mm7249a3. MMWR Morb Mortal Wkly Rep. 2023. PMID: 38060431 Free PMC article.
-
A Comparison with Adverse Events Following Immunization Associated with Sabin-Strains and Salk-Strains Inactivated Polio Vaccines in Zhejiang Province, China.Vaccines (Basel). 2022 Feb 17;10(2):319. doi: 10.3390/vaccines10020319. Vaccines (Basel). 2022. PMID: 35214777 Free PMC article.
-
Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China.Hum Vaccin Immunother. 2021 Aug 3;17(8):2568-2574. doi: 10.1080/21645515.2021.1898306. Epub 2021 Mar 29. Hum Vaccin Immunother. 2021. PMID: 33780310 Free PMC article.
-
Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.Lancet Infect Dis. 2021 Apr;21(4):559-568. doi: 10.1016/S1473-3099(20)30555-7. Epub 2020 Oct 23. Lancet Infect Dis. 2021. PMID: 33284114 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials